GUARDANT HEALTH INC

Guardant Health insider sale by CIO Kalia Kumud: a low‑impact trade amid FDA approval of Guardant360 CDx, indicating disciplined equity management and investor confidence.

Guardant Health insider sales reveal mixed signals—insiders trim 30k shares amid strong price momentum and valuation uncertainty, offering a nuanced view for investors.

Guardant Health’s chief legal officer sells 10,000 shares at $125.08—a disciplined portfolio move that signals confidence in the stock’s upcoming rally.

Guardant Health insider moves: COO Chris Freeman buys 24k shares at $32.86 and sells at $118.67, signaling confidence amid exec sell‑spree.

Guardant Health insider sales reveal routine portfolio moves amid strong fundamentals—learn how CEO and legal officer trades may signal confidence or caution for investors.

Guardant Health insider sale: CEO Talasaz AmirAli sells 50k shares at $100.32 while the stock soars 6% this week, confirming a buy‑and‑hold strategy and bullish outlook.

Guardant Health insider buys signal confidence: Mignone Roberto’s recent 264‑share purchase amid strong quarterly gains and new oncology partnership shows bullish outlook for investors.

Guardant Health insider purchase: Hidalgo Medina buys 232 shares at $91.07—neutral sign of confidence amid debt worries and leadership buy‑back activity.

Guardant Health insider buying by director Steve Krognes shows a steady confidence boost, with regular share purchases balanced by RSU sales, signaling long‑term belief in the company’s liquid‑biopsy technology.

Guardant Health insider sale: Tariq Musa sells 348 shares at $88.09—routine move that’s unlikely to shift stock price; investors see a neutral signal amid steady pipeline progress.